The well-established therapeutic target BRD4 is a member of the bromo- and extra-terminal domain (BET) family, which activates MYC’s enhancers, thereby maintaining its high oncogenic overexpression in KMT2A-r leukemia and other cancers. This evidence concerns the gene BRD4 and leukemia.